The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended six new medicines for approval at its October 2026 meeting. The recommended medicines include Rasonque (daraxonrasib) for the treatment of metastatic pancreatic cancer, Foundayo (orforglipron) for the treatment of a unspecified condition, Yuviwel (navepegritide) for the treatment of achondroplasia, Fovlussea (ranibizumab) and Neuzafy (filgrastim) as biosimilar medicines, and Kizfizo (temozolomide) as a hybrid medicine for the treatment of glioblastoma multiforme. Additionally, the CHMP has issued positive recommendations on extensions of therapeutic indications for several medicines, including Kyinsu (insulin icodec / semaglutide), pandemic influenza vaccine H5N1, Talvey (talquetamab), Tryngolza (olezarsen), and Tukysa (tucatinib).
European Medicines Agency Recommends Six New Medicines for Approval
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended six new medicines for approval at its October 2026 meeting.